RxDoctor Payments Data

Leah Terry

Acute Care · Lancaster, SCNPI 1437790490

Payments from drug & device makers

$963in general payments, 2019–2025

Across 69 payments — averaging $13.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$562
  • Johnson & Johnson$162
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$113
  • Ironwood Pharmaceuticals, Inc$33
  • Sanofi$30
  • Medtronic$19
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$963 in reported general payments places this provider in the 55th percentile of 339 acute care providers in South Carolina.

See all acute care providers in South Carolina

Medicare billing

Part B allowed, 2024
$64,795
Medicare patients
371
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin135$389,942
Skyrizi On-BodyRisankizumab-Rzaa17$303,907
Humira(Cf) PenAdalimumab18$175,350
LinzessLinaclotide172$164,906
Humira(Cf)Adalimumab12$60,623
IbsrelaTenapanor Hcl25$50,810
RinvoqUpadacitinib11$48,653
Dexlansoprazole DrDexlansoprazole75$24,620
MovantikNaloxegol Oxalate32$24,299
TrulancePlecanatide14$19,257
Lubiprostone36$8,637
Esomeprazole Magnesium74$6,112
Famotidine314$4,914
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates69$4,682
Pantoprazole Sodium322$3,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$113$409,199149 claims
AbbVieLinzess, Humira(Cf), Rinvoq$562$274,181195 claims
Ardelyx, Inc.Ibsrela$12$50,81025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 339 acute care providers in South Carolina.

Other acute care in Lancaster

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →